Replimune Securities Fraud Class Action Over FDA BLA Rejection
Analysis based on 139 articles · First reported Jul 29, 2026 · Last updated Sep 17, 2026
The litigation and the underlying FDA rejection of Replimune's BLA have severely damaged investor confidence in the company, with the stock reportedly losing the majority of its value across the April 2026 disclosures. Broader market impact is limited to the biotechnology sector, where the case reinforces regulatory and disclosure risk for single-asset clinical-stage developers, while the legal-services firms involved face no material market consequence.
Multiple investor-rights law firms have filed securities fraud class actions against Replimune Group (NASDAQ: REPL) and certain of its officers, alleging violations of federal securities laws during the class period of October 20, 2025 to April 10, 2026. The complaints allege that Replimune failed to address study design concerns previously communicated by the United States — Food and Drug Administration regarding its Biologics License Application for RP1 in combination with nivolumab, and that it submitted data from an early unplanned analysis of the RP1-104 study covering only 40 patients, roughly 10 percent of the planned 400-patient enrollment. On April 10, 2026, the FDA published a Complete Response Letter rejecting the BLA, finding that the evidence did not meet evidentiary standards for regulatory approval and that previously communicated study design concerns were not addressed. Replimune shares reportedly fell 19.46 percent to $4.76 on April 10, 2026, and then a further 64.29 percent to $1.70 on April 13, 2026. Firms including Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Levi & Korsinsky, Glancy Prongay & Murray, Robbins LLP, and Schall Brown & Schwartz LLP are soliciting investors, with a lead plaintiff deadline of October 5, 2026. The FDA had earlier published briefing documents on July 28, 2026 questioning the response assessment used in the IGNYTE study, which reportedly drove a 38.01 percent share decline that day.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard